Stock Expert AI

Content generated by AI editorial engine. Written by Stock Expert AI's research desk with AI assistance. Figures come from FMP data and the official sources cited in the article.

Merck & Co., Inc.
MRK - NYSE - $149.52 (as of ) ▲ +2.18%
-
Earnings Tue 2 Feb

Merck opens the
books on Tuesday evening.

The median of 25 price targets is $1651, stock is $150, +10.4% vs the analyst consensus median.

↓ summary below
Quick Take - in 40 seconds ·
C+
Council 2/6 - Historical V1 score 59

C+ — FMP rating1. Form 4: 6 transactions1.

Quick Answer

Merck & Co., Inc. (MRK) Q4 consensus: revenue $16.4B1, EPS $1.791. 7 consecutive quarters of beat1.

$1.79 EPS Estimate Last year $2.04 - -12% YoY
7 Beat Streak Expectations beaten consecutively for the last 7 quarters

Q3 FY26 EPS $2.49 vs $2.09 estimate: beat (+19.1%)1. Stock move on the next trading day: +2.2%1.

Next report

What to watch in Q4 FY26 (Feb 2, 2027)

  • EPS: consensus $1.79, against $2.04 in the same quarter a year ago (-12%).
  • Revenue: consensus $16.4B.

Watchlist

6 metrics stand out this quarter.

$66.8 billion Expectation / Guide

Fy2026 Revenue Guidance

Merck raised the midpoint of its FY2026 revenue guidance, narrowing the range to $66.8 billion-$67.3 billion, or 3% to 4% growth.

"We now expect revenue to be between $66.8 billion and $67.3 billion representing growth of 3% to 4% including a positive impact from foreign exchange of approximately 1 percentage point using mid October rates."

- Caroline Litchfield, CFO - Q3 FY26 Earnings Call - October 29, 2026
$694 million Investor Focus

Winrevair Growth

WINREVAIR global sales rose 94% to $694 million, aided partly by channel inventory.

Caroline Litchfield, CFO - Q3 FY26 Earnings Call - October 29, 2026
6% Investor Focus

Keytruda Q3 Growth

The KEYTRUDA family grew 6% to $8.6 billion in Q3.

Caroline Litchfield, CFO - Q3 FY26 Earnings Call - October 29, 2026
2027 Expectation / Guide

2027 Outlook Headwinds

2027_outlook_headwinds

Merck expects moderate top-line growth in 2027, with new launches and animal health partly offsetting more than $2 billion of generic and LOE headwinds.

Caroline Litchfield, CFO - Q3 FY26 Earnings Call - October 29, 2026
7-month Investor Focus

Sac Tmt Endometrial Data

sac-TMT's Phase III endometrial cancer study showed a near 7-month improvement in median overall survival versus chemotherapy.

Dean Y. Li, President of Merck Research Labs - Q3 FY26 Earnings Call - October 29, 2026
$550 million Investor Focus

Q3 Purchase Timing Benefit

Q3 sales were boosted by about $550 million from U.S. purchase timing, which will unwind largely in Q4 and in 2027.

Caroline Litchfield, CFO - Q3 FY26 Earnings Call - October 29, 2026

Stock Expert AI - Methodology

Do our scoring pillars, 6 perspectives, and Munger lens point in the same direction?

Council Score 2 / 6 Bullish

6 investor frameworks. 2 bullish (Ray Dalio, Ken Griffin), 0 bearish (none), 4 neutral (Jim Simons, Klarman, Buffett, Munger).

How is it calculated? ->
Ray Dalio macro - target upside +10.4%
Ken Griffin flow - 50d MA above
Jim Simons quant - RSI 57
Klarman value - target upside +10.4%
Buffett quality - ROE score 3/5
Munger valuation - target upside +10.4%
Munger's Mindset character & balance sheet lens
Fairly Valued

Quality business, trading at fair value.

How is it calculated? ->
Financial HealthWeak
Margin of SafetyModerate
Interest CoverageAdequate
ROIC vs WACCTight
Technical Levels - Pre-earnings positioning

What levels is the stock being tested at?

RSI(14)
56.9 RSI 56.9 positive momentum, 50d above
MACD
+1.80 price above 50d - support positive
50d MA
$147 stock 1.8% above - short-term support
200d MA
$127 stock 18.0% above - long-term support
Volume (10d)
+9% increase - pre-earnings positioning
Resistance
$165
Analyst median target - upgrade trigger if broken
Current
$150
Pre-earnings position
Support
$108
Invalidation - close below this is a technical breakdown
Pattern
Range
$108-$165 band - earnings breakout/breakdown trigger

Past Performance

4 quarters shown.

BEAT
Q4 FY25
$2.04 vs $2.01 est · Next-day price move: +2.1%
BEAT
Q1 FY26
$-1.28 vs $-1.47 est · Next-day price move: +2.7%
BEAT
Q2 FY26
$-0.13 vs $-0.27 est · Next-day price move: +0.3%
BEAT
Q3 FY26
$2.49 vs $2.09 est · Next-day price move: +2.2%

Three scenarios: what could happen?

Backlog concentration

No RPO/backlog concentration disclosed in Q3 earnings call.

Insider trading signal

Form 4 Q3 FY26: 6 transactions, net -$17.93M1.

Executive Action Amount Date
Guindo Chirfi EVP, Access, Policy & Comms Sale -$1.35M 2026-08-13
Zachary Jennifer EVP, General Counsel Sale -$10.72M 2026-08-13
DeLuca Richard R. EVP&Pres, Merck Animal Heallth Sale -$2.71M 2026-08-12
DeLuca Richard R. EVP&Pres, Merck Animal Heallth Sale -$973.2K 2026-08-12
DeLuca Richard R. EVP&Pres, Merck Animal Heallth Sale -$718.3K 2026-08-12
DeLuca Richard R. EVP&Pres, Merck Animal Heallth Sale -$1.46M 2026-08-12

6 transactions · 6 sales / 0 purchases = net negative flow. Not large in absolute terms against a $368.9B market cap.

CapEx shock

Q3 CapEx $893.0M1. Q3 op margin 40.6%1 - this level in Q4 is sensitive to CapEx revision risk.

Framework - Position discipline

After the data arrives: 3 scenarios, 3 windows

Not advice - a structural framework for earnings night. Decision discipline is yours.

Scenario A - Beat
Q4 EPS > $1.79 + CapEx discipline
Threshold: EPS > $1.791.
Target: Break above median target $1651; high target $1801 upper bound.
Scenario B - In-Line
EPS approx $1.79 + CapEx < $893.0M
Threshold: EPS approx $1.791, Q4 CapEx < $893.0M1.
Target: Consolidation in the band between current $1501 and median $1651.
Scenario C - Miss
EPS < $1.74 or CapEx >= $893.0M
Threshold: EPS < $1.741.
Current price $150 — above SMA200 $1271.

Market Outlook

What do analysts say? 25 price targets · 28 ratings

Wall Street Consensus
$165
12-month median target price (+10.4% gap to the analyst consensus median)
19
BUY
9
HOLD
0
SELL
Risk Management
$108
Invalidation level - critical support threshold
$147 - 50-day MA (above, +1.8%)
$127 - 200-day MA (above, +18.0%)
IV Crush risk (sudden drop in inflated option premiums before earnings): Option premiums are inflated before earnings.
Verdict - MRK Q4 FY26
C+

You read it in 5 minutes. When the numbers come out on Tuesday evening - you know what you're looking at.

Data arrives at night. The framework is ready now.

Data arrives on Tuesday evening. The framework is ready on this page: Q4 EPS threshold $1.791, CapEx threshold "below $893.0M". Two anchors, three scenarios.

Comparison Stock Expert AI is free today — no credit card.

3 subscriptions. 1 platform.

Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts

Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing

Stock Expert AI is free today — no credit card. Council 6-lens analysis + MoonshotScore multi-pillar + Insider tracker + Technical levels - all in one platform, for every stock.

Educational tool, not investment advice. Past performance does not guarantee future results.

Calendar

Catalyst Calendar - 90-day forward look

Feb 2, 2027EARNINGSQ4 FY26 results (after market close) + earnings call
Feb 3, 2027PRICEFirst trading day after earnings - 200dMA test + IV crush
Mar 1, 2027 – Mar 31, 2027FILING10-K due within 60–90 days of fiscal year end (by Mar 1, 2027 – Mar 31, 2027); the exact deadline depends on filer status
~May 5, 2027EARNINGSQ1 FY27 (next quarter, date not yet scheduled in FMP)

DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.

Frequently Asked Questions

What does the MRK Q4 FY26 earnings preview cover?

This Merck & Co., Inc. (MRK) Q4 FY26 earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.

What should investors watch for in MRK Q4 FY26 earnings?

Merck & Co., Inc. (MRK): Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.

Where do the numbers on this page come from?

Merck & Co., Inc. (MRK): Figures are sourced from Financial Modeling Prep (FMP) fundamentals and consensus data plus official earnings-call transcripts; derived metrics are labeled with their source next to each figure.

Is this a buy or sell recommendation?

Merck & Co., Inc. (MRK): No. This page is educational research, not investment advice. It summarizes analyst consensus and company data; consult a licensed financial advisor before making any investment decision.

More earnings, decoded